Transplantation & Cellular Therapy

The latest news, research, and perspectives in transplantation and cellular therapy. Autologous and allogeneic stem cell transplantation represent potentially curative options for some patients, while the field of non-transplant cellular therapies, such as chimeric antigen receptor T-cell therapy, is also expanding to offer more patients curative options.

Cecilia BrownTransplantation & Cellular Therapy | December 2, 2022
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Read More
Leah SherwoodTransplantation & Cellular Therapy | November 29, 2022
Children with R/R B-cell ALL who received co-administered CD19-and CD22-directed CAR-T therapy had a 99% CR.
Cecilia BrownTransplantation & Cellular Therapy | November 29, 2022
Allogeneic CAR T-cells had “encouraging safety and efficacy” in patients with CD7-positive hematologic malignancies.
Cecilia BrownTransplantation & Cellular Therapy | November 29, 2022
Axicabtagene ciloleucel led to higher response rates and higher toxicity rates than tisagenlecleucel in R/R DLBCL.
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in heavily pretreated patients...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
Certain genetic features in tumor and plasma samples from patients with LBCL are associated with poor CD19-directed CAR-T...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
CD19-directed CAR T-cell therapy led to a complete remission in approximately half of patients...
Leah SherwoodMyeloma | October 25, 2022
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
Leah SherwoodTransplantation & Cellular Therapy | October 25, 2022
Researchers have recently identified bacterial proliferation on the skin as a factor associated with the development of...
Leah SherwoodMyeloproliferative Neoplasms | October 12, 2022
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Leah SherwoodTransplantation & Cellular Therapy | October 11, 2022
Dr. Lentzsch and Dr. Wong discuss the role of transplantation in newly diagnosed systemic light chain (AL) amyloidosis...
Leah SherwoodMeeting News | October 6, 2022
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown
Leah SherwoodTransplantation & Cellular Therapy | October 6, 2022
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
A conditioning regimen of clofarabine plus total body irradiation prior to allogeneic hematopoietic stem cell transplantation ...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
Researchers had not previously studied the long-term impact of omidubicel...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
New research suggests venetoclax-containing regimens with intensive treatment and allogeneic hematopoietic stem cell ...
Leah SherwoodMyeloma | September 30, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
Cecilia BrownTransplantation & Cellular Therapy | September 15, 2022
The combination led to an overall survival rate of nearly 75% in patients with BPDCN...
Cecilia BrownTransplantation & Cellular Therapy | September 15, 2022
First-line treatment with tagraxofusp led to an overall response rate of 75% in patients with blastic plasmacytoid...
Kerri FitzgeraldTransplantation & Cellular Therapy | September 13, 2022
Blood Cancers Today spoke with clinicians about the two available second-line chimeric antigen receptor T-cell therapies...
Leah SherwoodAcute Myeloid Leukemia | August 16, 2022
A second allogeneic hematopoietic stem cell transplantation (HSCT) is a reasonable treatment option for patients with ...
Leah SherwoodTransplantation & Cellular Therapy | August 10, 2022
The largest study yet comparing chimeric antigen receptor (CAR) T-cell therapy with the previous standard of care (SOC)...
Leah SherwoodPrint | August 9, 2022
In second-line therapy for relapsed/refractory LBCL, which patients would you consider eligible for CAR T-cell therapy...
Cecilia BrownPrint | August 8, 2022
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
Leah SherwoodAcute Lymphoblastic Leukemia | August 8, 2022
Advances have been accomplished in the management of adults with acute lymphoblastic leukemia...
Leah SherwoodTransplantation & Cellular Therapy | August 6, 2022
The CAR T-cell therapy received accelerated approval for adults with R/R FL after two or more lines of systemic therapy.
Leah SherwoodChronic Lymphocytic Leukemia | August 5, 2022
This article discusses the state of the art of how to manage the most difficult cases of chronic CLL with a focus on two ...
Leah SherwoodAcute Myeloid Leukemia | August 4, 2022
Patients with acute myeloid leukemia (AML) who received a venetoclax/azacitidine combination prior to allogeneic ...
Leah SherwoodAggressive B-Cell Lymphoma | August 4, 2022
Researchers have demonstrated the clinical importance of COVID-19 vaccination after anti-CD19 chimeric antigen receptor (CAR) ...
Leah SherwoodTransplantation & Cellular Therapy | August 4, 2022
Transplant was associated with a lower incidence of disease relapse but did increase the mortality related to treatment.
Leah SherwoodTransplantation & Cellular Therapy | August 4, 2022
Nearly a third of patients with chronic graft-versus-host disease (GVHD) were able to discontinue long-term systemic therapy ...
Leah SherwoodTransplantation & Cellular Therapy | August 2, 2022
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation and Rare Pediatric...
Leah SherwoodTransplantation & Cellular Therapy | July 29, 2022
The FDA has granted Fast Track Designation and Rare Pediatric Disease Designation for WU-CART-007.
Cecilia BrownTransplantation & Cellular Therapy | July 26, 2022
Patients with newly diagnosed primary central nervous system lymphoma who received high-dose chemotherapy and autologous ...
Cecilia BrownAggressive B-Cell Lymphoma | July 25, 2022
Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell treatment, improved quality of life compared to standard of care ...
Leah SherwoodTransplantation & Cellular Therapy | July 20, 2022
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application from Cellenkos, Inc. to ...
Leah SherwoodTransplantation & Cellular Therapy | July 19, 2022
Axicabtagene ciloleucel is the most cost-effective chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed ...
Leah SherwoodTransplantation & Cellular Therapy | July 13, 2022
Results from the global, phase III TRANSFORM study support liso-cel as a new second-line treatment recommendation in patients ...
Leah SherwoodTransplantation & Cellular Therapy | July 12, 2022
In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ...
Leah SherwoodTransplantation & Cellular Therapy | July 12, 2022
The overall efficacy of tisagenlecleucel was similar between the two groups. Flu/Cy led to more profound lymphocytopenia ...
Kerri FitzgeraldAcute Lymphoblastic Leukemia | June 24, 2022
This article discusses optimizing transplant-related care for patients with high-risk acute lymphoblastic...
Kerri FitzgeraldAggressive B-Cell Lymphoma | June 23, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use recommended the conditional approval ...
Leah LawrencePrint | June 23, 2022
Clinicians who specialize in BPDCN discuss the disease and novel therapeutic approaches to treating patients with BPCDN.
Leah SherwoodAcute Lymphoblastic Leukemia | June 13, 2022
There was a global increase of 6.2% in autologous HSCT and 7.0% in allogeneic HSCT.
Leah LawrenceTransplantation & Cellular Therapy | June 13, 2022
Researchers retrospectively analyzed 580 patients with AML receiving HSCT between January 1999 and November 2020.
Kerri FitzgeraldTransplantation & Cellular Therapy | June 6, 2022
Median PFS and OS were 25.8 months (95% CI, 9.6-47.6) and 46.6 months (95% CI, 24.9-not estimable), respectively.
Leah LawrenceTransplantation & Cellular Therapy | May 31, 2022
Autologous hematopoietic stem cell transplantation improved survival outcomes for certain patients younger than 65.
Leah LawrenceAggressive B-Cell Lymphoma | May 26, 2022
CAR T-cell dysfunction marked by TIGIT expression may be driving poor response to therapy in patients with non-Hodgkin ...
Leah LawrenceMyeloma | May 5, 2022
Few patients with myeloma benefit from CAR-T cell therapy, according to a Viewpoint.
Leah LawrenceTransplantation & Cellular Therapy | May 5, 2022
Black and Hispanic patients who underwent CAR T-cell therapy had outcomes comparable to their White and Asian counterparts.
Leah LawrenceTransplantation & Cellular Therapy | April 21, 2022
A study of seven clinical trials around CAR T-cell therapies showed a substantially low enrollment of participants who were ...
Leah LawrenceTransplantation & Cellular Therapy | April 11, 2022
University of Pennsylvania researchers have shortened the cell manufacturing process for CAR T-cell therapy, which is ...
Leah LawrenceTransplantation & Cellular Therapy | March 2, 2022
With increasing evidence of efficacy as front-line treatment in relapsed/refractory disease, clinicians are excited to see ...
Sabrina AhleIndolent B-Cell Lymphoma | March 2, 2022
Allogene Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to resume trials of its allogeneic ...
Sabrina AhleTransplantation & Cellular Therapy | March 2, 2022
Director of the U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence Richard Pazdur, MD, has ...
Sabrina AhleTransplantation & Cellular Therapy | February 25, 2022
On Feb. 15, Robert Califf, MD, was confirmed to lead the FDA as commissioner for the second time.
While the field of telehealth grew rapidly in the United States during the COVID-19 pandemic, many patients lack access to ...
Sabrina AhleTransplantation & Cellular Therapy | February 25, 2022
In January, a private equity firm announced that it would buy MarketScan, a group of databases containing sensitive patient ...
Sabrina AhleTransplantation & Cellular Therapy | February 8, 2022
The Government Accountability Office says the US Department of Health and Human Services is at high risk of mismanaging a ...
Sabrina AhleAggressive B-Cell Lymphoma | February 8, 2022
The FDA has approved an update to the prescribing information for all approved indications of axi-cel.
Sabrina AhleTransplantation & Cellular Therapy | February 7, 2022
On average, pharmaceutical companies raised US list prices on cancer, diabetes, and other prescription drugs by 6.6% in the ...
Sagar Lonial, MD, FACPMyeloma | February 2, 2022
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Susan O'Brien, MDAcute Lymphoblastic Leukemia | February 1, 2022
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Sabrina AhleTransplantation & Cellular Therapy | January 21, 2022
Abatacept has been U.S. Food and Drug Administraion (FDA)-approved as acute graft-versus-host disease (aGVHD) prophylaxis for ...
Brandon MayTransplantation & Cellular Therapy | January 21, 2022
Life expectancy has improved since 1974 but remains 20.8% lower compared with the general population.
Leah LawrenceAggressive B-Cell Lymphoma | January 8, 2022
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
Leah LawrenceAggressive B-Cell Lymphoma | January 8, 2022
According to data from the ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) ...
Rebecca AraujoTransplantation & Cellular Therapy | September 28, 2021
Black patients with multiple myeloma (MM) who receive upfront hematopoietic autologous cell transplantation (ASCT) have ...
Rebecca AraujoMantle Cell Lymphoma | September 23, 2021
A study found that for people with mantle cell lymphoma (MCL), patient demographics were associated with likelihood of ...
Rebecca AraujoTransplantation & Cellular Therapy | September 14, 2021
A study found that Black Americans are underrepresented in clinical trials supporting approval of oral chemotherapy drugs ...
Rebecca AraujoTransplantation & Cellular Therapy | August 23, 2021
A study published in Bone Marrow Transplantation evaluated whether patient characteristics impacted the timeline to return to ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | August 18, 2021
Experts focus on the latest news and clinical development and impact for multiple myeloma.
Rob DillardTransplantation & Cellular Therapy | August 12, 2021
The use of hematopoietic stem cell transplantation (AHCT) is associated with excellent 2-year outcomes in multiple myeloma ...
Rob DillardMyeloma | August 6, 2021
A study found no discernible difference in the usage rate of hematopoietic cell transplantation (HCT) between Black and White ...
Rob DillardMyeloma | July 26, 2021
Patient race and ethnicity were bound to be associated with hematopoietic stem/progenitor cells (HSPC) mobilization, ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 7, 2021
Janssen and Legend Biotech announced new data for BCMA-directed CAR-T cell therapy cilta-cel for relapsed/refactory MM.
Rob DillardTransplantation & Cellular Therapy | June 30, 2021
A study did not observe racial disparities in the use of autologous hematopoietic cell transplantation (HCT) consolidative ...
Rebecca AraujoMyeloma | May 24, 2021
Real-world data showed that upfront autologous hematopoietic stem cell transplantation (AHCT) for treatment of multiple ...
Rebecca AraujoMyeloma | May 17, 2021
Researchers from The Mount Sinai Health System in New York City evaluated racial disparities in time to autologous ...
Rebecca AraujoTransplantation & Cellular Therapy | May 17, 2021
Infection is a major driver of intensive care unit (ICU) admissions after hematopoietic cell transplantation (HCT), according ...
Nikhil Munshi, MDTransplantation & Cellular Therapy | April 27, 2021
Nikhil Munshi, MD, had a conversation with Orsi Giricz, PhD, from LLS, to discuss the recent approval of Abecma and his role ...
Rebecca AraujoTransplantation & Cellular Therapy | March 30, 2021
The U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (ide-cel) for the treatment of adults with ...
Rebecca AraujoTransplantation & Cellular Therapy | March 9, 2021
A study published in Clinical Lymphoma, Myeloma & Leukemia evaluated the burden of outpatient autologous hematopoietic ...
Parameswaran Hari, MDMyeloma | March 5, 2021
Parameswaran Hari, MD, weighs in on clinical considerations for selecting CAR T cell therapy for multiple myeloma.
Rebecca AraujoTransplantation & Cellular Therapy | March 2, 2021
The latest updates from the KarMMA trial, published in The New England Journal of Medicine, showed that treatment with ...
Rebecca AraujoTransplantation & Cellular Therapy | February 17, 2021
Patients with multiple myeloma who underwent double autologous hematopoietic cell transplantation did not have better overall ...
Rebecca AraujoMyeloma | January 22, 2021
An analysis of patients with multiple myeloma (MM) who underwent autologous hematopoietic cell transplant (AHCT) showed that ...
Rebecca AraujoTransplantation & Cellular Therapy | January 5, 2021
The novel chimeric antigen receptor (CAR) T cell therapy, CT053, achieved a 100% overall response rate (ORR) for the ...
Rebecca AraujoTransplantation & Cellular Therapy | January 5, 2021
Results from the PRIME study found that P-BCMA-101, an autologous CAR T-cell therapy, was effective and safe for patients ...
Nina Shah, MDMyeloma | December 2, 2020
Nina Shah, MD, talks about two multiple myeloma agents granted priority review by the FDA and data on these therapeutics.
Rob DillardTransplantation & Cellular Therapy | December 2, 2020
A study published in the Journal of Clinical Oncology found that ixazomib maintenance therapy extended survival in patients ...
Ankit Kansagra, MDMyeloma | December 2, 2020
Ankit Kansagra, MD, discusses chimeric antigen receptor T-cell agents in the pipeline for multiple myeloma.
Cecilia BrownMeeting News | January 1, 1970
Patients with CMML who received an allogeneic HSCT earlier in the course of their disease had better outcomes.
Advertisement
Advertisement
Advertisement
Latest Posts

November 15, 2022

Advertisement